390 related articles for article (PubMed ID: 8938284)
21. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?
Brister SJ; Ofosu FA; Buchanan MR
Thromb Haemost; 1993 Aug; 70(2):259-62. PubMed ID: 8236131
[TBL] [Abstract][Full Text] [Related]
22. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
[TBL] [Abstract][Full Text] [Related]
23. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
[TBL] [Abstract][Full Text] [Related]
24. Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass.
Shirota K; Watanabe T; Takagi Y; Ohara Y; Usui A; Yasuura K
Artif Organs; 2000 Jan; 24(1):49-56. PubMed ID: 10677157
[TBL] [Abstract][Full Text] [Related]
25. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.
Kuitunen A; Hiippala S; Vahtera E; Rasi V; Salmenperä M
Acta Anaesthesiol Scand; 2005 Oct; 49(9):1272-9. PubMed ID: 16146463
[TBL] [Abstract][Full Text] [Related]
26. Inflammo-coagulatory response, extrinsic pathway thrombin generation and a new theory of activated clotting time interpretation.
Gil W
Perfusion; 2001 Jan; 16(1):27-35. PubMed ID: 11192304
[TBL] [Abstract][Full Text] [Related]
27. Aprotinin and hemostasis monitoring concerns during cardiac surgery.
Swartz MF; Fink GW; Searles B
J Extra Corpor Technol; 2004 Dec; 36(4):375-83. PubMed ID: 15679283
[TBL] [Abstract][Full Text] [Related]
28. Restoration of the normal coagulation process: advances in therapies to antagonize heparin.
D'Ambra M
J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S58-62. PubMed ID: 8938285
[TBL] [Abstract][Full Text] [Related]
29. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
30. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers.
Slaughter TF; LeBleu TH; Douglas JM; Leslie JB; Parker JK; Greenberg CS
Anesthesiology; 1994 Mar; 80(3):520-6. PubMed ID: 8141448
[TBL] [Abstract][Full Text] [Related]
31. The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation.
Tanaka KA; Szlam F; Levy JH
Br J Haematol; 2006 Jul; 134(1):77-82. PubMed ID: 16803571
[TBL] [Abstract][Full Text] [Related]
32. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement.
Wendel HP; Heller W; Gallimore MJ; Bantel H; Müller-Beissenhirtz H; Hoffmeister HE
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):41-5. PubMed ID: 7681331
[TBL] [Abstract][Full Text] [Related]
33. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage.
Mössinger H; Dietrich W
Ann Thorac Surg; 1998 Jun; 65(6 Suppl):S45-50; discussion S50-1, S74-6. PubMed ID: 9647138
[TBL] [Abstract][Full Text] [Related]
34. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations.
Dietrich W; Mössinger H; Spannagl M; Jochum M; Wendt P; Barankay A; Meisner H; Richter JA
J Thorac Cardiovasc Surg; 1993 Apr; 105(4):712-20. PubMed ID: 7682267
[TBL] [Abstract][Full Text] [Related]
35. Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits.
Ernofsson M; Thelin S; Siegbahn A
Scand J Thorac Cardiovasc Surg; 1995; 29(4):157-65. PubMed ID: 8789468
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques.
Owings JT; Pollock ME; Gosselin RC; Ireland K; Jahr JS; Larkin EC
Arch Surg; 2000 Sep; 135(9):1042-7. PubMed ID: 10982508
[TBL] [Abstract][Full Text] [Related]
37. Increased anticoagulation during cardiopulmonary bypass by prostaglandin E1.
Kozek-Langenecker SA; Wanzel O; Berger R; Kettner SC; Coraim F
Anesth Analg; 1998 Nov; 87(5):985-8. PubMed ID: 9806669
[TBL] [Abstract][Full Text] [Related]
38. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
de Smet AA; Joen MC; van Oeveren W; Roozendaal KJ; Harder MP; Eijsman L; Wildevuur CR
J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
[TBL] [Abstract][Full Text] [Related]
39. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
[TBL] [Abstract][Full Text] [Related]
40. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass.
Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M
Circulation; 1995 Nov; 92(9):2579-84. PubMed ID: 7586360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
